Revisiones en Cáncer 00079 / http://dx.doi.org/10.20960/revcancer.00079
Resumen| PDF

Revisión

Cetuximab en el cáncer de células escamosas de cabeza y cuello


Ana Callejo Pérez, Cristina Bayona Antón, María Liliana Cabrera Pinos, Laura Calvo Otero, Laura Viña Gopar, Lina Marcela Valencia Cárdenas, María García González

Prepublicado: 2024-07-11

Logo Descargas   Número de descargas: 123      Logo Visitas   Número de visitas: 25      Citas   Citas: 0

Compártelo:


El cetuximab es un anticuerpo monoclonal anti-EGFR que, hasta la actualidad, representa la única terapia biológica dirigida aprobada para el tratamiento de los carcinomas escamoso de cabeza y cuello. El cetuximab es un tratamiento efectivo y bien tolerado tanto en el contexto de enfermedad locorregional como en la situación de enfermedad metastásica o recurrente. Durante su desarrollo se ha evidenciado su actividad sinérgica en concomitancia con radioterapia, con beneficio en supervivencia por encima de la radioterapia sola, y aunque con resultados inferiores al platino, representa una opción para pacientes frágiles no candidatos a quimioterapia. Así mismo, el cetuximab dentro del esquema EXTREME se había establecido como primera línea en el tratamiento de la enfermedad recurrente o metastásica en la era pre-inmunoterapia. No obstante, los esquemas en combinación con taxanos, platino o fluoropirimidinas continúan siendo una opción de tratamiento en progresión a inmunoterapia o en pacientes no candidatos a la misma. En la actualidad, el cetuximab continúa formando parte del arsenal terapéutico para tratar a los pacientes con carcinomas escamoso de cabeza y cuello tanto en enfermedad local como en enfermedad metastásica, representando una opción terapéutica eficaz y bien tolerada, y con un papel activo a lo largo de la evolución de la enfermedad de estos pacientes.

Palabras Clave: Cetuximab. Tratamiento anti-EGFR. Carcinoma escamoso de cabeza y cuello.



Chow LQM. Head and Neck Cancer. N Engl J Med. 2020;382(1):60-72.
DOI: 10.1056/NEJMra1715715
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015;33(29):3235-42.
DOI: 10.1200/JCO.2015.61.6995
Huang SH, O’Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18(7):40.
DOI: 10.1007/s11864-017-0484-y
Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996;78(6):1284-92.
DOI: 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X
Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Review of Anticancer Therapy. 2006;6(11):1539-52.
DOI: 10.1586/14737140.6.11.1539
Cruz JJ, Ocaña A, Del Barco E, Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol. 2007;18(3):421-30.
DOI: 10.1093/annonc/mdl175
Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021;13:1758835920949418.
DOI: 10.1177/1758835920949418
Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget.2016;7(45):74362-79.
DOI: 10.18632/oncotarget.11413
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39.
DOI: 10.1056/NEJMoa040938
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-65.
DOI: 10.1056/NEJMoa0804385
Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697-710.
DOI: 10.1016/S1470-2045(13)70181-5
Machiels JP, Specenier P, Krauß J, Dietz A, Kaminsky MC, Lalami Y, et al. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2015;76(1):13-20.
DOI: 10.1007/s00280-015-2761-4
Stewart JSW, Cohen EEW, Licitra L, Van Herpen CML, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 10 de abril de 2009;27(11):1864-71.
Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77-85.
DOI: 10.1200/JCO.2004.06.075
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359(11):1116-27.
DOI: 10.1056/NEJMoa0802656
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology. 2010;11(1):21-8.
DOI: 10.1016/S1470-2045(09)70311-0
Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160-74.
DOI: 10.1056/NEJMra0707704
Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1(11):1311-8.
Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res. 2000;6(11):4343-50.
Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6(6):2166-74.
Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18(21 Suppl):47S-53S.
Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000;6(12):4874-84.
Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002;8(5):994-1003.
Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19(13):3234-43.
DOI: 10.1200/JCO.2001.19.13.3234
Bonner JA. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine. 2006.
DOI: 10.1056/NEJMoa053422
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. JCO. 2014;32(27):2940-50.
DOI: 10.1200/JCO.2013.53.5633
Gebre-Medhin M, Brun E, Engström P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. JCO. 2021;39(1):38-47.
DOI: 10.1200/JCO.20.02072
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40-50.
DOI: 10.1016/S0140-6736(18)32779-X
Hitt R, Mesía R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol. 2022;134:106087.
DOI: 10.1016/j.oraloncology.2022.106087
Sun L, Candelieri-Surette D, Anglin-Foote T, Lynch JA, Maxwell KN, D’Avella C, et al. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2022;148(11):1022-8.
DOI: 10.1001/jamaoto.2022.2791
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, et al. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. Int J Cancer. 2020;147(1):107-15.
DOI: 10.1002/ijc.32736
Zandberg DP, Cullen K, Bentzen SM, Goloubeva OG. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. Oral Oncol. 2018;86:132-40.
DOI: 10.1016/j.oraloncology.2018.09.023
Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, et al. Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. JCO. 2010;28(1):8-14.
DOI: 10.1200/JCO.2009.23.0425
Marín-Jiménez JA, Oliva M, Peinado Martín P, Cabezas-Camarero S, Plana Serrahima M, Vázquez Masedo G, et al. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy. Front Oncol. 2022;12:953020.
DOI: 10.3389/fonc.2022.953020
Keil F, Hartl M, Altorjai G, Berghold A, Riedl R, Pecherstorfer M, et al. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial. Eur J Cancer. 2021;151:201-10.
DOI: 10.1016/j.ejca.2021.03.051
Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, et al. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016;96(1):21-9.
DOI: 10.1016/j.ijrobp.2016.04.030
Mesía R, Vázquez S, Grau JJ, García-Sáenz JA, Lozano A, García C, et al. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2016;94(2):289-96.
DOI: 10.1016/j.ijrobp.2015.10.019
Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol. 2017;28(9):2219-24.
DOI: 10.1093/annonc/mdx300
Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234. JCO. 2014;32(23):2486-95.
DOI: 10.1200/JCO.2013.53.9163
Mesía R, Rueda A, Vera R, Lozano A, Medina JA, Aguiar D, et al. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial. Ann Oncol. 2013;24(2):448-53.
DOI: 10.1093/annonc/mds291
Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy. JCO. 1 de junio de 2007;25(16):2171-7.
Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24(18):2866-72.
DOI: 10.1200/JCO.2005.04.3547
Vermorken JB, Remenar E, Hitt R, Kawecki A, Rottey S, Knierim L, et al. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial. JCO. 2014;32(15_suppl):6021-6021.
DOI: 10.1200/jco.2014.32.15_suppl.6021
Bossi P, Miceli R, Locati LD, Ferrari D, Vecchio S, Moretti G, et al. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 2017;28(11):2820-6.
DOI: 10.1093/annonc/mdx439
Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Annals of Oncology. 2015;26(9):1941-7.
DOI: 10.1093/annonc/mdv268
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-75.
DOI: 10.1016/S1470-2045(20)30755-5
Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016-22.
DOI: 10.1093/annonc/mdr367
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, et al. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2023;13:1226939.
DOI: 10.3389/fonc.2023.1226939
Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology. 2013;84(5):284-9.
DOI: 10.1159/000345453
Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, et al. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 2022;28(11):2329-38.
DOI: 10.1158/1078-0432.CCR-21-3849
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. The Lancet Oncology. 2021;22(6):883-92.
DOI: 10.1016/S1470-2045(21)00136-4
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, et al. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1583.
DOI: 10.1001/jamaoncol.2018.1888
Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, et al. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody. ESMO Open. 2024;9(6):103476.
DOI: 10.1016/j.esmoop.2024.103476

Revisión: Tratamiento de la enfermedad recurrente irresecable o metastásica

María Plana Serrahima , Ricard Mesía Nin

Revisión: Carcinoma escamoso localmente avanzado e irresecable

Julio José Lambea Sorrosal , María Zapata García , Alba Moratiel Pellitero , Karla Andrea Osorio Macassi , Isabel Pajares Bernad , Inés Ruiz Moreno , Sara Esteras Per

Revisión: Inmunoterapia en el carcinoma escamoso de cabeza y cuello

Santiago Cabezas-Camarero

Artículos más populares

Revisión: Valoración de la calidad de vida en pacientes supervivientes de cáncer de cabeza y cuello

El tratamiento del cáncer de cabeza y cuello (CCC)...

Publicado: 2024-03-11

Revisión: Estadios iniciales del cáncer de cabeza y cuello. Papel de la cirugía

En el cáncer de cabeza y cuello la cirugía queda r...

Publicado: 2024-03-12

Revisión: Carcinoma de cabeza y cuello en pacientes no candidatos a platino

El cisplatino es un componente esencial del tratam...

Publicado: 2024-03-19

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.